Clinical Trial Update: Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 safety study of enzalutamide (MDV3100) in patients with incurable breast cancer has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)

Snippet

Sponsor: Pfizer | Conditions: Breast Cancer | Phase 1 | Status: COMPLETED | Results posted: 2019-05-08